Hem › Triplenegativ bröstcancer › North Carolina › Durham
Kliniska studier för Triplenegativ bröstcancer i Durham, NC
12 studier för Triplenegativ bröstcancer söker deltagare vid platser i och runt Durham (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekryterarFas 1/2
- Duke University, Durham
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RekryterarFas 2
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi bort
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekryterarFas 3
- Duke Cancer Institute, Durham
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi bort
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
RekryterarFas 2
- Duke University, Durham
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekryterarFas 2/3
- Duke Cancer Institute, Durham
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
RekryterarFas 2
- Duke University Medical Center, Durham
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
RekryterarFas 1
- University of North Carolina, Chapel Hill · 10 mi bort
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekryterarFas 1
- Duke Cancer Institute /ID# 276267, Durham
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RekryterarFas 2
- The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi bort
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
RekryterarFas 2
- University of North Carolina, Chapel Hill · 10 mi bort
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
RekryterarFas 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi bort
A Study of NX-1607 in Adults With Advanced Malignancies
RekryterarFas 1
- University of North Carolina, Chapel Hill · 10 mi bort
Triplenegativ bröstcancer-studier i andra städer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andra studier i Durham
- Bröstcancer64 studier
- Cancer (alla typer)58 studier
- Icke-småcellig lungcancer39 studier
- Multipelt myelom37 studier
- Akut myeloid leukemi33 studier
- Metastaserande cancer33 studier
- Prostatacancer32 studier
- Lungcancer32 studier
- Kolorektal cancer28 studier
- Äggstockscancer27 studier
- Kronisk lymfatisk leukemi27 studier
- Hjärtsvikt26 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.